Compile Data Set for Download or QSAR
Report error Found 840 Enz. Inhib. hit(s) with all data for entry = 9849
TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493065(US10981911, Example 6 | 2-((1r,4r)-4-(2-(2-Oxo-2-(...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493067(US10981911, Example 8 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493068(US10981911, Example 9 | 2-((1r,4r)-4-(2-(1H-1,2,4-...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(US10294226, Compound Ex. 6 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493070(US10981911, Example 11 | 2-((1r,4r)-4-(2-(Oxazol-4...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493071(US10981911, Example 12 | 2-((1r,4r)-4-(2-(2-(4-Hyd...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493072(US10981911, Example 13 | 2-Cyano-N-((1-((1r,4r)-4-...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493073(US10981911, Example 14 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493074(US10981911, Example 15 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493075(US10981911, Example 16 | 2-((1r,4r)-4-(2-(2H-1,2,3...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493076(US10981911, Example 17A | (E)-N-((1-((1r,4r)-4-(Cy...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493078(US10981911, Example 18 | 2-((1r,4r)-4-(2-(2-(3-Hyd...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493079(US10981911, Example 19 | N-((1r,4r)-4-(Cyanomethyl...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493080(US10981911, Example 20 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493081(US10981911, Example 21 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387824(US10294226, Compound Ex. 7 | N-(2-Cyano-2-methylpr...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493083(US10981911, Example 23 | N-(4-Cyanobicyclo[2.2.1]h...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493084(US10981911, Example 24 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493085(US10981911, Example 25 | 2-((1r,4r)-4-(2-((1H-Pyra...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527405(CHEMBL4456630 | US10981911, Example 26)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493087(US10981911, Example 27 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493088(US10981911, Example 28 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493089(US10981911, Example 29 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(US10294226, Compound Ex. 3 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493090(US10981911, Example 30 | N-((1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493091(US10981911, Example 31 | 2-((1r,4r)-4-(2-(4-Chloro...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493092(US10981911, Example 32 | N-((3R,5R)-Adamantan-1-yl...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527407(CHEMBL4582390 | US10981911, Example 33)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387825(US10294226, Compound Ex. 8 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493095(US10981911, Example 35 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493096(US10981911, Example 36 | N-((1H-imidazol-2-yl)meth...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493097(US10981911, Example 37 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387826(US10294226, Compound Ex. 9 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493099(US10981911, Example 39 | N-(4-Cyanobenzyl)-2-(1-((...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493100(US10981911, Example 40 | 1-((1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493101(US10981911, Example 41 | 2-((1r,4r)-4-(2-(Thiazol-...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493102(US10981911, Example 42 | 2-((1S,4r)-4-(2-(2-((S)-3...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493103(US10981911, Example 43 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493104(US10981911, Example 44 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527406(CHEMBL4588333 | US10981911, Example 45)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493106(US10981911, Example 46 | Phenyl ((1-((1r,4r)-4-(cy...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493107(US10981911, Example 47 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493108(US10981911, Example 48 | N-Benzyl-2-(1-((1r,4r)-4-...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493109(US10981911, Example 49 | 2-((1r,4r)-4-(2-(2-Oxo-2-...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493110(US10981911, Example 50 | 2-((1r,4r)-4-(2-(3-Hydrox...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493111(US10981911, Example 51 | 2-((1r,4r)-4-(2-(2-Aminop...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493112(US10981911, Example 52 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 840 total ) | Next | Last >>
Jump to: